Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2

Clinics

Volumn 67, Issue SUPPLEMENT, 2012, Pages 149-154

  Tavares, Marcos R ^a   Toledo, Sérgio P A ^a   Montenegro, Fábio L M ^a   Moyses, Raquel A ^a   Toledo, Rodrigo A ^a   Sekyia, Tomoko ^a   Cernea, Claudio R ^a   Brandão, Lenine G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Carcinoma; Medullary; Multiple Endocrine Neoplasia; Surgery

Indexed keywords

CALCITONIN; PROTEIN RET;

BLOOD; CHILD; GENETICS; HUMAN; LYMPH NODE DISSECTION; MEDULLARY CARCINOMA; MUTATION; NECK; REVIEW; SIPPLE SYNDROME; THYROID TUMOR;

CALCITONIN; CARCINOMA, MEDULLARY; CHILD; GERM-LINE MUTATION; HUMANS; LYMPH NODE EXCISION; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NECK; PROTO-ONCOGENE PROTEINS C-RET; THYROID NEOPLASMS;

EID: 84863914510     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.6061/clinics/2012(Sup01)25     Document Type: Review

References (36)

1. Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, et al. The relationship between specific RET protooncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575-9.
2. Thakker RV. Multiple endocrine neoplasia-syndromes of the twentieth century. J Clin Endocrinol Metab. 1998;83(8):2617-20, http://dx.doi.org/10.1210/jc.83.8.2617.
3. Lourenço DM Jr, Toledo RA, Coutinho FL, Margarido LC, Siqueira SA, dos Santos MA, et al. The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1. Clinics. 2007;62(4):465-76, http://dx.doi.org/10.1590/S1807-59322007000400014.
4. Toledo RA, Lourenço DM, Coutinho FL, Quedas E, Mackowiack I, Machado MC, et al. Novel MEN1 germline mutations in Brazilian families with multiple endocrine neoplasia type 1. Clin Endocrinol (Oxf). 2007;67(3):377-84, http://dx.doi.org/10.1111/j.1365-2265.2007.02895.x.
5. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86(12):5658-71, http://dx.doi.org/10.1210/jc.86.12.5658.
6. Eng C. Mendelian genetics of rare-and not so rare-cancers. Ann N Y Acad Sci. 2010;1214:70-82, http://dx.doi.org/10.1111/j.1749-6632.2010.05789.x.
7. Toledo SP, dos Santos MA, Toledo RA, Lourenço DM Jr. Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2. Clinics. 2006;61(1):59-70, http://dx.doi. org/10.1590/S1807-59322006000100011.
8. Correia-Deur JE, Toledo RA, Imazawa AT, Lourenço DM Jr, Ezabella MC, Tavares MR, et al. Sporadic medullary thyroid carcinoma: clinical data from a university hospital. Clinics. 2009;64(5):379-86, http://dx.doi.org/10.1590/S1807-59322009000500002.
9. Lips CJ, Höppener JW, Van Nesselrooij BP, Van der Luijt RB. Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines. J Intern Med. 2005;257(1):69-77, http://dx.doi.org/10.1111/j.1365-2796.2004.01429.x.
10. Machens A, Dralle H. Multiple endocrine neoplasia type 2: achievements and current challenges. Clinics. 2012;67(S1):113-8, http://dx.doi.org/10.6061/clinics/2012(Sup01)19.
11. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National CancerData Base report on 53,856 cases of thyroid carcinoma treated in the US, 1985-1995. Cancer. 1998;83(12):2638-48, http://dx.doi.org/10.1002/(SICI)1097-0142(19981215)83:12,2638::AID-CNCR31.3.0.CO;2-1.
12. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T. Longterm outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol. 2006;155(2):229-36, http://dx.doi.org/10.1530/eje.1.02216.
13. Pelizzo MR, Boschin IM, Bernante P, Toniato A, Piotto A, Pagetta C, et al. Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients. Eur J Surg Oncol. 2007;33(4):493-7, http://dx.doi.org/10.1016/j.ejso.2006.10.021.
14. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27(5):535-60, http://dx.doi.org/10.1210/er.2006-0017.
15. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565-612, http://dx.doi.org/10.1089/thy.2008.0403.
16. Tavares MR, Michaluart P Jr, Montenegro F, Arap S, Sodre M, Takeda F, et al. Skip metastases in medullary thyroid carcinoma: a single-center experience. Surg Today. 2008;38(6):499-504, http://dx.doi.org/10.1007/s00595-007-3664-8.
17. Machens A, Lorenz K, Dralle H. Individualization of lymph node dissection in RET (Rearranged During Transfection) carriers at risk for medullary thyroid cancer: value of pre-therapeutic calcitonin levels. Ann Surg. 2009;250(2):305-10, http://dx.doi.org/10.1097/SLA.0b013e318 1ae333f.
18. Schlumberger M, Massicotte MH, Nascimento CL, Chougnet C, Baudin E, Leboulleux S. Kinase inhibitors for advanced medullary thyroid carcinoma. Clinics. 2012;67(S1):125-9, http://dx.doi.org/10.6061/clinics/2012(Sup01)21.
19. Toledo SP, Lourenço DM Jr, Santos MA, Tavares MR, Toledo RA, Correia-Deur JE. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics. 2009;64(7):699-706, http://dx.doi.org/10.1590/S1807-59322009000700015.
20. Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist. 2011;16(1):49-52, http://dx.doi.org/10.1634/theoncologist.2010-0344.
21. Erlic Z, Rybicki L, Peczkowska M, Golcher H, Kann PH, Brauckhoff M, et al. Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients. Clin Cancer Res. 2009;15(20):6378-85, http://dx.doi.org/10.1158/1078-0432.CCR-09-1237.
22. Sherman SI, Angelos P, Ball DW, Byrd D, Clark OH, Daniels GH, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2007;5(6):568-621.
23. Tincani AJ, Teixeira GV, Tavares MR, Hojaij FC, AraÚjo PPC, Maia AL, et al. Diretrizes Clínicas na SaÚde Suplementar. Assoc. Med. Brasil. e Age{inverted breve}ncia Nacional de SaÚde Suplementar. Câncer Medular de Tireoide: Tratamento. http://www.projetodiretrizes.org.br/ans/diretrizes/cancer_ medular_de_tireoide-tratamento.pdf.
24. Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemmeau JL, et al. Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Français d'Etude des Tumeurs Endocrines. J. Clin Endocrinol Metab. 2011;96(3):E509-18, http://dx.doi.org/10.1210/jc.2010-1234.
25. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann Surg. 2003;237(3):399-407, http://dx.doi.org/10.1097/01.SLA.0000055273.58908.19.
26. Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153-8, http://dx.doi.org/10.1089/thy.2009.0159.
27. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells SA Jr. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. New Engl J Med. 2005;353(11):1105-13, http://dx.doi.org/10.1056/NEJMoa043999.
28. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, et al. Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat. 2011;32(1):51-8, http://dx.doi.org/10.1002/humu.21385.
29. Ahmed SR, Ball DW. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment. J Clin Endocrinol Metab. 2011;96(5):1237-45, http://dx.doi.org/10.1210/jc.2010-2359.
30. Toledo SP, Ferraz AR. Multiple endocrine type II neoplasm. Rev Hosp Clin Fac Med Sao Paulo. 1990;45(1):1-2.
31. Ezabella MC, Hayashida CY, Bisi H, Leite MO, Borelli A, Abelin NM, et al. Early detection of medullary thyroid carcinoma in multiple endocrine neoplasia type II. Rev Hosp Clin Fac Med Sao Paulo. 1990;45(3):105-9.
32. Hayashida CY, Alves VA, Kanamura CT, Ezabella MC, Abelin NM, Nicolau W, et al. Immunohistochemistry of medullary thyroid carcinoma and C-cell hyperplasia by an affinity-purified anti-human calcitonin antiserum. Cancer. 1993;72(4):1356-63, http://dx.doi.org/10.1002/1097-0142(19930815)72:4,1356::AID-CNCR2820720434.3.0.CO;2-0.
33. Nunes AB, Ezabella MC, Pereira AC, Krieger JE, Toledo SP. A novel Val648Ile substitution in RET protooncogene observed in a Cys634Arg multiple endocrine neoplasia type 2A kindred presenting with an adrenocorticotropin-producing pheochromocytoma. J Clin Endocrinol Metab. 2002;87(2):5658-61, http://dx.doi.org/10.1210/jc.2002-020345.
34. Santos MA, Nunes AB, Abelin N, Ezabella MC, Toledo RA, Lourenço DM Jr, et al. Genetic screening of multiple endocrine neoplasia type 2: experience of the USP Endocrine Genetics Unit. Arq Bras Endocrinol Metabol. 2006;50(1):7-16, http://dx.doi.org/10.1590/S0004-273020 06000100003.
35. Santos MA, Quedas EP, Toledo Rde A, Lourenço DM Jr, Toledo SP. Screening of RET gene mutations in multiple endocrine neoplasia type-2 using conformation sensitive gel electrophoresis (CSGE). Arq Bras Endocrinol Metabol. 2007;51(9):1468-76, http://dx.doi.org/10.1590/S0004-27302007000900009.
36. Toledo RA, Wagner SM, Coutinho FL, Lourenço DM Jr, Azevedo JA, Longuini VC, et al. High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. J Clin Endocrinol Metab. 2010;95(3):1318-27, http://dx.doi.org/10.1210/jc.2009-1355.